BioNTech Prepares To Launch COVID-19 Shot For 5 to11 Year Old: Reuters

BioNTech SE BNTX is reportedly prepping a launch for its mRNA-based COVID-19 vaccine developed with Pfizer Inc PFE for children between 5 and 11 years old.
Also read: Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years.
BioNTech CMO Özlem Türeci told the weekly German magazine, Der Spiegel, that the Company would file the results of its trial in 5- to 11-year-olds with regulators across the world "over the next few weeks," reported Reuters.
The Company also said that the final production steps are being adjusted to bottle a lower-dose pediatric vaccine version.
"Things are looking good, everything is going according to plan," CEO Ugur Sahin told Der Spiegel.
The Pfizer/BioNTech vaccine is currently authorized for children as young as 12 years old, and back in August became the first COVID-19 vaccine to secure full FDA approval for people 16 years and older.
Related Content: FDA Schedules Adcomm For Pfizer/BioNTech's COVID-19 Booster Shot.
European Medicines Agency and CDC backed the use of Pfizer-BioNTech COVID-19 Vaccine For 12-15 Age Group.
Moderna Inc MRNA began recruiting in March to test the mRNA jab in kids younger than 12 years.
In July New York Times reported that Pfizer, BioNTech, and Moderna would expand vaccine trials in children ages five to 11.
Price Action: PFE stock is down 0.89% at $45.63, BNTX stock is up 0.93% at $354.64 during the market session on the last check Friday.
Photo by x3 from Pixabay